Memento Medicines Nets $93M for Retinal Disease Antibody

A significant capital infusion is set to accelerate the development of a novel therapeutic approach for debilitating retinal conditions. Memento Medicines has successfully closed a $93 million Series A financing round, a substantial sum aimed at advancing its lead bispecific antibody candidate, MMT-205, through crucial preclinical and early clinical stages. This funding positions the company to tackle complex diseases like neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

The financing was co-led by prominent life science investors Forbion, RA Capital Management, and Avego BioScience Capital, underscoring strong confidence in Memento's scientific premise. Additional backing came from notable participants including Sanofi Ventures and Samsara BioCapital. These funds will be instrumental in supporting the IND-enabling studies for MMT-205, with the ambitious goal of initiating human clinical trials in 2027. The market for retinal disease treatments is substantial, with anti-VEGF therapies already generating billions annually, yet significant unmet needs persist, driving demand for innovative solutions.

MMT-205 represents a dual-action strategy, designed to simultaneously activate the Tie2 receptor and inhibit Vascular Endothelial Growth Factor (VEGF). This combination therapy, licensed exclusively from MabTics Co., Ltd and Curacle Co., Ltd, aims to overcome the limitations of current anti-VEGF monotherapies. By promoting retinal vascular integrity through Tie2 activation while blocking pathological angiogenesis with VEGF inhibition, MMT-205 shows promise in preclinical models for superior efficacy and a potentially improved therapeutic profile.

The formation of Memento Medicines itself is a product of strategic innovation. The company is the fifth entity to emerge from Sera Medicines, an antibody accelerator established in collaboration with RA Capital in 2023. This accelerator model focuses on identifying and advancing promising biologic candidates, providing a robust framework for rapid development and commercialization. The successful licensing of MMT-205 from its South Korean partners, MabTics and Curacle, highlights the global reach of this innovation pipeline.

The leadership team at Memento Medicines, spearheaded by CEO Naveen Daryani, expressed enthusiasm for the investor syndicate's deep expertise in ophthalmology. This collective knowledge is expected to be invaluable as the company navigates the complex path from laboratory to patient. The strategic involvement of investors like Forbion, with its proven track record in building successful ophthalmology ventures, further bolsters Memento's prospects.

The therapeutic potential of MMT-205 is rooted in its ability to address the complex biological pathways driving retinal vascular diseases. Preclinical data suggests that its dual mechanism offers enhanced Tie2 activation and improved retinal vasculature integrity compared to existing treatments. This differentiated approach could offer a significant advancement for patients suffering from nAMD and DME, conditions that severely impact vision and quality of life for millions worldwide. The successful closing of this Series A round signifies a critical step towards realizing this potential.